PATENT CLAIM ANALYSIS

Application Number: 16114076
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-01
Patent Classification: ["514", "415000"]

Abstract:
Methods and compositions for treating acute myeloid leukemia and diffuse large B cell lymphoma using combinations of venetoclax and indolinone derivatives are provided.

Claim (Index 9):
The method of  claim 8 , wherein the anti-CD20 monoclonal antibody is rituximab.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 96.0
- Lexical Diversity: 1.09091
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15660566', '15680905', '15461327', '15357876', '14877708']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7666505314178225
- 35 USC 102 Novelty (BERT): 0.5657264789336278
- Combined Prediction Score: 0.7465581261694031
- Mean Citation Score: 397.409042
- Max Citation Score: 540.7462
- Similarity Product: 284.14707597208024

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test